What is HC Wainwright's Forecast for ZNTL Q2 Earnings?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Research analysts at HC Wainwright raised their Q2 2025 EPS estimates for shares of Zentalis Pharmaceuticals in a research note issued to investors on Thursday, May 15th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.43) for the quarter, up from their prior estimate of ($0.52). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals' Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.44) EPS, FY2025 earnings at ($1.97) EPS, FY2026 earnings at ($2.12) EPS, FY2027 earnings at ($2.12) EPS, FY2028 earnings at ($1.50) EPS and FY2029 earnings at ($0.57) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, meeting the consensus estimate of ($0.67).

Other equities research analysts also recently issued reports about the company. Wedbush reiterated a "neutral" rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. UBS Group reduced their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Finally, Wells Fargo & Company reduced their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a research note on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $8.24.

Zentalis Pharmaceuticals Stock Down 3.2%

Shares of Zentalis Pharmaceuticals stock traded down $0.04 on Monday, reaching $1.20. The company's stock had a trading volume of 778,244 shares, compared to its average volume of 1,554,957. The company has a market capitalization of $86.34 million, a price-to-earnings ratio of -0.48 and a beta of 1.81. The firm's fifty day simple moving average is $1.38 and its two-hundred day simple moving average is $2.26. Zentalis Pharmaceuticals has a 52 week low of $1.01 and a 52 week high of $13.00.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers acquired 21,000 shares of the business's stock in a transaction dated Wednesday, April 30th. The stock was purchased at an average price of $1.40 per share, with a total value of $29,400.00. Following the transaction, the director now directly owns 281,192 shares in the company, valued at approximately $393,668.80. The trade was a 8.07% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.90% of the company's stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Barclays PLC grew its holdings in Zentalis Pharmaceuticals by 18.5% during the third quarter. Barclays PLC now owns 75,395 shares of the company's stock valued at $277,000 after purchasing an additional 11,748 shares during the period. SG Americas Securities LLC grew its holdings in Zentalis Pharmaceuticals by 115.6% during the fourth quarter. SG Americas Securities LLC now owns 56,389 shares of the company's stock valued at $171,000 after purchasing an additional 30,240 shares during the period. Savant Capital LLC bought a new stake in Zentalis Pharmaceuticals during the fourth quarter valued at about $72,000. Ieq Capital LLC bought a new position in shares of Zentalis Pharmaceuticals during the 4th quarter valued at approximately $46,000. Finally, Anfield Capital Management LLC grew its stake in shares of Zentalis Pharmaceuticals by 100.0% during the 4th quarter. Anfield Capital Management LLC now owns 129,318 shares of the company's stock valued at $392,000 after acquiring an additional 64,659 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.